- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
August 2, 2016
May 25, 2016
May 23, 2016
Irvine, CA – April 13, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, announced today that it has entered into a strategic partnership with Worthington Industries (NYSE: WOR), maker of cryogenic storage vessels and equipment. Through this partnership, Worthington’s CryoScience by Taylor Wharton business will design and manufacture biostorage and logistics equipment for use in Cryoport’s life sciences cryogenic logistics solutions.
New consulting and advisory division extends Cryoport's expertise in cryogenic logistics to the life sciences industry
- - -
Irvine, CA – April 11, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, announced the launch of a new Temperature Controlled Logistics Consulting Division to assist life sciences companies in developing strategies for global cold chain logistics management and contingency options to protect their valuable, and often irreplaceable, biological commodities.
Irvine, Calif., April 4, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, today announced it is providing cryogenic logistics solutions that support ProteoGenex, Inc.'s (“ProteoGenex”) shipping of biological specimens, including PBMCs, BMMCs, frozen tissue, OCT-embedded tissue, blood serum, blood plasma, whole blood, RNA/DNA, and other bio-fluids.
UPS Temperature True® Cryo keeps products frozen at -150° C, and provides monitoring, intervention and financial risk mitigation
BRUSSELS, March 15, 2016 -- UPS (NYSE: UPS) announced the launch of UPS Temperature True® Cryo in Europe, providing healthcare customers access to end-to-end product protection and capability to ship parcels in a cryogenic environment. The service includes real-time tracking and intervention, which, when combined with UPS’s risk mitigation solutions and global network of control towers, will provide complete visibility for shipments at every stage of the supply chain journey.
March 3, 2016
Irvine, CA – March 3, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, today announced that it will be supporting the cryogenic logistics requirements of ImmunoCellular Therapeutics’ (NYSE MKT: IMUC) (“ImmunoCellular”) registrational Phase III glioblastoma clinical trial across 120 sites in North America and Europe. This clinical trial is designed to evaluate the safety and efficacy of ImmunoCellular’s lead product candidate ICT-107, a patient-derived dendritic cell-based immunotherapy.
- - -
Cryoport’s advanced cold chain logistics solutions are increasingly crucial to enabling life sciences development
Irvine, CA – February 16, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the world’s leading cryogenic logistics company, announced today that it will manage the cryogenic shipping of solid tumor samples and vaccine for Perseus PCI’s (“Perseus”) melanoma and ovarian cancer clinical trials.